ibi351,cetuximab,GFH925
innovent biologics,Zhejiang genfleet therapeutics,eli lilly
['rectal', 'colorectal', 'ibi351', 'innovent']
innovent presents phase 1 clinical data of ibi351 (krasg12c inhibitor) as monotherapy for metastatic colorectal cancer at the 2023 asco annual meeting 
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.